Development-stage pharma company developing proprietary IRR with peptide-based platform which activates the body's innate natural immune system to regenerate tissue and reduce inflammation across a broad range of acute and chronic diseases. Araim has demonstrated efficacy in a wide variety of human disease models, successfully translated positive preclinical findings in clinical trials, developed a library of 10 compounds and 4 routes of administration, and secured an extensive patent portfolio. Lead asset, cibinetide, brings a transformational product to the global neuropathy market, based upon the ability to regrow nerve fibers, modify the disease course, and deliver an improved safety profile. Cibinetide is preparing for Phase 3 in a lead orphan indication and phase 2b in diabetic peripheral neuropathy. Araim is seeking pharmaceutical partners to develop and commercialize the platform or individual assets.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):